Related Experiment Video
Updated: Aug 8, 2026
05:37
Stenosis of the Inferior Vena Cava: A Murine Model of Deep Vein Thrombosis
Published on: December 22, 2017
[Venous thromboembolism and cancer]
E Ferrari1, M Benhamou, N Berkane
1Hôpital Pasteur, CHU, service de cardiologie, 30, avenue de la Voie romaine, 06002 Nice.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|January 25, 2002
Summary
Malignant disease increases the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). Current approaches to prevention and treatment in cancer patients are evolving, with anticoagulants showing a favorable benefit/risk profile.
Area of Science:
- Oncology
- Hematology
- Vascular Medicine
Context:
- Malignant diseases are a significant risk factor for developing deep venous thrombosis (DVT) and pulmonary embolism (PE).
- Thromboembolic events can be the initial presentation of an occult cancer or a major complication in diagnosed malignancy.
- Existing epidemiological data on cancer-associated thrombosis is substantial, yet limitations in diagnostic investigations persist.
Purpose:
- To review the evolving strategies in the primary prevention and treatment of thromboembolic disease in cancer patients.
- To address the changing paradigms in managing deep venous thrombosis (DVT) and pulmonary embolism (PE) in the context of malignancy.
- To evaluate the benefit/risk ratio of anticoagulant therapy in patients with cancer and thromboembolic events.
Summary:
- Cancer patients face increased risks of deep venous thrombosis (DVT) and pulmonary embolism (PE), presenting either as an initial sign of occult cancer or a complication of diagnosed malignancy.
- Management strategies for cancer-associated thrombosis are shifting, with promising results in primary prevention trials and evolving treatment protocols.
- Anticoagulant therapy in cancer patients requires a careful benefit/risk assessment, often revealing a favorable profile, and antithrombotic agents may possess anticancer effects.
Impact:
- Highlights the need for updated clinical guidelines for managing thromboembolic complications in oncology.
- Encourages a re-evaluation of anticoagulant use in cancer patients, moving beyond historical concerns.
- Suggests potential dual benefits of antithrombotic agents in treating both thrombosis and malignancy.
Related Concept Videos
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...